Z. Oum'hamed

发表

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment.

E. Van Cutsem, J. Tabernero, T. Yoshino, 2016, Clinical colorectal cancer.

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-blind, Placebo-controlled Phase III Trial of Nintedanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Advanced Colorectal Cancer Refractory to Standard Treatment

J. Tabernero, T. Yoshino, E. Cutsem, 2015 .

A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

H. Staines, O. Bouché, J. Capdevila, 2011 .

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

E. Van Cutsem, H. Lenz, J. Stoehr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.

A. Carrato, E. Van Cutsem, M. Ducreux, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

In vitro reactions of human osteoblasts in culture with zirconia and alumina ceramics.

M. Lorenzato, D. Laurent-Maquin, J. Adnet, 1999, Journal of biomedical materials research.

A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer

M. Ducreux, O. Bouché, A. Gramont, 2008 .

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.

E. Felip, T. Owonikoko, D. Morgensztern, 2021, Journal of Clinical Oncology.

Matrix metalloproteinases MMP-2, -9 and tissue inhibitors TIMP-1, -2 expression and secretion by primary human osteoblast cells in response to titanium, zirconia, and alumina ceramics.

R. Garnotel, D. Laurent-Maquin, Y. Josset, 2004, Journal of biomedical materials research. Part A.

DNA image cytometry and Ag-NORs-staining application in biocompatibility studies on human osteoblast cells in vitro.

M. Lorenzato, D. Laurent-Maquin, J. Adnet, 1998, Biomaterials.

gastrointestinal tumours, colorectalNintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

H. Lenz, J. Tabernero, F. Ciardiello, 2016 .

Examination of Zirconia, Alumina Ceramics and Titanium Interactions on Human Osteoblasts in Culture

C. Trentesaux, D. Laurent-Maquin, C. Dupont, 2000 .